Unknown PHASE1 INTERVENTIONAL 1-arm NCT03050411

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Sponsor: Peking University Third Hospital

Interventions Apatinib Mesylate Tablets EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)

Updated 6 times since 2017 Last updated: Feb 9, 2017 Started: May 31, 2016 Primary completion: Jun 30, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03050411, this PHASE1 trial focuses on Nonsmall Cell Lung Cancer and remains ongoing. Sponsored by Peking University Third Hospital, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University Third Hospital

Data source: Peking University Third Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China